Riccardo Soffietti

Riccardo Soffietti's AcademicInfluence.com Rankings

Riccardo Soffietti

Physics

#7204

World Rank

#9217

Historical Rank

physics Degrees

Download Badge

Physics

Riccardo Soffietti's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Riccardo Soffietti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Riccardo Soffietti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. (2021) (2388)
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. (2011) (1001)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) (736)
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014) (601)
A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. (2013) (558)
Response assessment criteria for brain metastases: proposal from the RANO group. (2015) (553)
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. (2016) (550)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial (2009) (547)
EANO guidelines for the diagnosis and treatment of meningiomas. (2016) (524)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) (486)
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force (2010) (453)
Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force (2011) (437)
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) (2017) (312)
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. (2015) (303)
Epidemiology of glial and non-glial brain tumours in Europe. (2012) (264)
Prognostic factors in well-differentiated cerebral astrocytomas in the adult. (1989) (228)
Management of brain metastases (2002) (224)
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis (2018) (222)
Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. (2012) (215)
Epilepsy and brain tumors (2010) (210)
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force (2006) (206)
Updates in the management of brain metastases. (2016) (194)
Leptomeningeal metastases: a RANO proposal for response criteria (2014) (193)
Brain metastases. (2019) (182)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. (2019) (166)
PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. (1998) (158)
The Evolving Landscape of Brain Metastasis. (2018) (146)
Brain metastases (2019) (146)
Brain metastases: current management and new developments (2008) (144)
EANO guidelines for the diagnosis and treatment of ependymal tumors. (2018) (134)
A prognostic gene expression signature in infratentorial ependymoma (2012) (133)
Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. (2014) (132)
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. (2016) (127)
Ependymomas in Adults (2010) (125)
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria (2014) (120)
Histologic prognostic factors in ependymoma (1991) (117)
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. (2013) (115)
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. (2013) (109)
PET imaging in patients with brain metastasis-report of the RANO/PET group. (2019) (108)
EANO guideline on the diagnosis and management of meningiomas. (2021) (101)
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. (2015) (98)
Mechanisms and Therapy for Cancer Metastasis to the Brain (2018) (96)
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life (2011) (93)
Ependymoma: internal correlations among pathological signs: the anaplastic variant. (1991) (88)
The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma (2008) (88)
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. (2018) (86)
Primitive cerebral melanoma: case report and review of the literature. (2001) (82)
The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection (2020) (81)
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications (2019) (81)
Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. (2013) (77)
Targeted therapy in brain metastasis (2012) (74)
Management of brain metastases according to molecular subtypes (2020) (73)
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology) (2013) (72)
Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression. (2019) (71)
Ependymomas of the adult: molecular biology and treatment (2008) (71)
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma (2017) (68)
Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring (2018) (66)
Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial (2019) (65)
Prognostic value of histologic factors in adult cerebral astrocytoma (1988) (60)
Natural history and management of brainstem gliomas in adults (2008) (56)
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target (2020) (56)
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study. (2009) (53)
Breast cancer brain metastasis: molecular mechanisms and directions for treatment. (2018) (52)
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. (2016) (50)
Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System (2013) (48)
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. (2016) (47)
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. (2021) (45)
Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study (1995) (44)
Brain metastases from unknown primary tumour (2001) (44)
Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors. (2006) (44)
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
Neurologic complications of chemotherapy and other newer and experimental approaches. (2014) (42)
MGMT promoter methylation in plasma of glioma patients receiving temozolomide (2014) (42)
Radiotherapy and chemotherapy of brain metastases (2005) (42)
Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe (2016) (40)
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas. (2020) (40)
What is New in the Management of Epilepsy in Gliomas? (2015) (38)
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. (2018) (37)
Second‐line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy (2004) (36)
Brain metastases from unknown primary tumour: a prospective study. (2001) (31)
Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. (2020) (29)
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. (2017) (29)
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. (2016) (29)
Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001 (2017) (27)
Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. (2014) (27)
Phase 0 and Window of Opportunity Clinical Trial Design in Neuro-Oncology: A RANO Review. (2020) (27)
Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study (2017) (26)
EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic (2020) (25)
Primary Lymphomas of the Brain: A Clinico-Pathologic Review of 37 Cases (1987) (24)
Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance (2021) (23)
Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps (2016) (23)
MRI diagnosis of intramedullary metastases from extra-CNS tumors (2007) (23)
Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). (2019) (22)
A comprehensive characterization of mitochondrial DNA mutations in glioblastoma multiforme. (2015) (22)
Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. (2017) (22)
What have we learned from trials on antiangiogenic agents in glioblastoma? (2014) (22)
Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas (2016) (21)
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma (2015) (21)
New developments in the treatment of malignant gliomas (2007) (20)
Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis (2019) (20)
Caveolin 1 Expression Independently Predicts Shorter Survival in Oligodendrogliomas (2009) (19)
8704 Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases results of the EORTC 22952–26001 study (2009) (18)
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016 (2019) (18)
Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy (2004) (18)
Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2019) (17)
Chemotherapy of anaplastic oligodendroglial tumours (2004) (17)
Anti-angiogenic approaches to malignant gliomas. (2012) (16)
Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). (2011) (15)
Paraneoplastic opsoclonus: a neuropathologic study of two cases. (1989) (15)
Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study. (2009) (15)
A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: The NeuroCOVID‐19 Task Force of the European Academy of Neurology (2021) (15)
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches (2021) (15)
On the nature of the so-called monstrocellular sarcoma of the brain. (1980) (15)
Delayed adverse effects after irradiation of gliomas: clinicopathological analysis (2005) (15)
Association between multiple sclerosis and oligodendroglioma. Case report. (1981) (15)
Supratotal Resection of Glioblastoma: Is Less More? (2019) (14)
Addition of Thiotepa and Rituximab to Antimetabolites Significantly Improves Outcome in Primary CNS Lymphoma: First Randomization of the IELSG32 Trial. (2015) (14)
Antiangiogenic therapy of brain tumors: the role of bevacizumab (2014) (14)
Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments (2018) (14)
Skin metastases of glioblastoma in the absence of intracranial progression are associated with a shift towards a mesenchymal immunophenotype: report of two cases (2009) (13)
Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians (2014) (13)
Rare glial tumors. (2016) (13)
The Neurologic Assessment in Neuro-Oncology (NANO) Scale: A Tool to Assess Neurologic Function for Integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria (S22.005) (2014) (13)
Overview on current treatment standards in high-grade gliomas. (2018) (13)
Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept (2016) (13)
Treatment of brain metastasis: current status and future directions (2016) (12)
Management of Brain and Leptomeningeal Metastases from Breast Cancer (2020) (12)
Radio- and chemotherapy of malignant gliomas. Pathological changes in the normal nervous tissue (2005) (12)
Ependymoma: internal correlations among pathological signs (1991) (12)
European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL). (2022) (12)
The legend of cytomegalovirus and glioblastoma lives on. (2014) (11)
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours (2019) (11)
Primary prevention of COVID‐19: Advocacy for vaccination from a neurological perspective (2021) (11)
Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersocieties (SINch/AINO/SIN) document. (2020) (11)
Brain metastases (2021) (11)
Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2021) (11)
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism (2022) (11)
Does valproic acid affect tumor growth and improve survival in glioblastomas? (2016) (11)
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. (2019) (10)
The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. (2021) (10)
Molecularly based management of gliomas in clinical practice (2015) (10)
Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome (2019) (10)
Controversies in management of low-grade gliomas in light of new data from clinical trials. (2017) (10)
Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series (2018) (10)
Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study (2020) (10)
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. (2017) (10)
Pathology of human malignant gliomas after radiation and chemotherapy (2005) (10)
Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Versus Delayed Administration (2018) (9)
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis (2008) (9)
A call from the European Academy of Neurology on COVID-19 (2020) (9)
Vascular response to irradiation in malignant gliomas (1990) (9)
Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance (1994) (9)
Low-grade gliomas. (2012) (8)
The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. (2009) (8)
Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors. (2010) (8)
Temozolomide in rare brain tumors of the adult: a prospective study (2005) (8)
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination (2010) (8)
Imaging and clinical end points in brain metastases trials. (2017) (8)
Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview (2021) (8)
Author Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis (2018) (7)
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas (2004) (7)
Current clinical management of elderly patients with glioma (2020) (7)
Evaluation of the 2020 European Academy of Neurology virtual congress: transition from a face‐to‐face to a virtual meeting (2020) (7)
Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. (2019) (7)
Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents (2020) (7)
Lonidamine in malignant brain tumors. (1991) (6)
Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors. (2022) (6)
Extent of surgery in low-grade gliomas: an old question in a new context. (2018) (6)
Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. (2016) (6)
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors (2019) (6)
Correction to: Efficacy of initial temozolomide for high‑risk low grade gliomas in a phase II AINO (Italian Association for Neuro‑Oncology) study: a post‑hoc analysis within molecular subgroups of WHO 2016 (2019) (6)
The position of the neurologist in neuro‐oncology 1 (2002) (6)
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. (2019) (6)
COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper (2022) (6)
What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas? (2018) (6)
New chemotherapy options for the treatment of malignant gliomas (2007) (6)
Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. (2022) (6)
Treatment of gliomatosis cerebri with temozolomide: A retrospective study of the AINO (Italian Association for Neuro- Oncology) (2007) (6)
Basic mechanisms of epilepsy (2002) (6)
Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage (2015) (5)
Brain Metastasis as Complication of Systemic Cancers (2018) (5)
Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program (2022) (5)
IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. (2021) (5)
Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group. (2022) (5)
Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand? (2022) (5)
Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9-15, 2014). (2014) (5)
Phase II trial of bevacizumab and fotemustine in recurrent grade III gliomas. (2012) (5)
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study (2017) (5)
Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: A phase II AINO study (2008) (5)
A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis (2022) (5)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Leptomeningeal metastases from non-small cell lung cancer: state of the art and recent advances (2020) (4)
Neuro-oncology: new insights and advances in treatment (2008) (4)
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? (2020) (4)
Evidence-based management of adult patients with diffuse glioma - Authors' reply. (2017) (4)
Richter’s Syndrome of the Central Nervous System (2021) (4)
PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) (2019) (4)
Screening for Tumours in Paraneoplastic Syndromes (2011) (4)
Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature (2021) (4)
Natural History and Spontaneous Prognostic Factors (2013) (4)
Guidelines on the Management of Low-grade Gliomas: EANO Task Force Report (2012) (4)
Oral Scientific SessionsComparison of Local Control of Brain Metastasis with Stereotactic Radiosurgery Versus Surgical Resection: A Secondary Analysis of EORTC 22952-26001 (2017) (4)
Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects (2022) (3)
Efficacy of radiation therapy on epileptic seizures of grade 2 and 3 gliomas: A retrospective study. (2011) (3)
A drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent local relapse and treat established brain metastasis (2020) (3)
Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. (2017) (3)
O9.09EFFICACY AND TOLERABILITY OF LACOSAMIDE IN PATIENTS WITH GLIOMA: A PROSPECTIVE STUDY. (2014) (3)
Ependymoma: Evaluation and Management Updates (2022) (3)
Editorial to Special Issue (2013) (3)
A phase II study of first-line temozolomide and second-line PCV in recurrent/progressive malignant gliomas. (2004) (3)
Neuro-oncology perspective of treatment options in metastatic breast cancer. (2018) (3)
Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO). (2012) (3)
Automatic segmentation and therapy follow-up of cerebral glioma in diffusion-tensor images (2010) (3)
MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide. (2014) (3)
P14.42 Neratinib for treatment of leptomeningeal metastases from HER2-positive breast cancer in extended access program: preliminary results (2021) (3)
Targeted Therapies in Rare Brain Tumours (2021) (3)
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology (2018) (3)
Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response (2016) (3)
Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS). (2018) (3)
Pineal Gland Tumors (1993) (3)
Strategies to prevent brain metastasis. (2019) (3)
Systemic Therapy for Lung Cancer Brain Metastases (2021) (3)
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2022) (3)
Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419). (2019) (3)
Tissue alterations induced by radio- and chemotherapy in brain with malignant gliomas. (1981) (3)
Histologic and clinical factors of prognostic significance in astrocytic gliomas. (1990) (3)
Radiotherapy as salvage treatment for immunocompetent primary non-Hodgkin's CNS lymphomas: An Italian study (2000) (2)
Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. (2012) (2)
Does Whole-Brain Radiation Therapy for Oligometastatic Brain Metastases Translate Into a Survival Benefit for Patients With a Limited Competing Risk From Extracranial Disease? A Secondary Analysis of EORTC 22952-26001 (2016) (2)
EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology (2012) (2)
Evaluation of changes in gliomas structural features after chemotherapy using DTI-based Functional Diffusion Maps ( fDMs ) : a preliminary study with intraoperative correlation (2010) (2)
Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis? (2016) (2)
Effects of radiotherapy on the astrocytomatous areas of malignant gliomas (2004) (2)
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis (2018) (2)
Second-line PCV in recurrent or progressive glioblastomas: A phase II study (2006) (2)
A Pathologic Study of Malignant Gliomas Operated after Radio- and Chemotherapy (1981) (2)
Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study (2016) (2)
Reply to M.C. Chamberlain and C. Gemici. (2013) (2)
Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy. (2016) (2)
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. (2022) (2)
O8.01PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY IN TREATING LOW GRADE GLIOMAS IN ELOQUENT AREAS (2014) (1)
Medical and Neuro-Oncology (2010) (1)
Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy? (2022) (1)
Medulloblastoma in adults: an analysis of clinico-pathological, molecular and treatment factors. (2021) (1)
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. (2022) (1)
P14.77 Efficacy and safety of Tumor-Treating Fields associated with Depatux M and metronomic temozolomide for recurrent glioblastoma: a case-report (2021) (1)
8719 Salvage therapy with bevacizumab and fotemustine in recurrent high grade gliomas (2009) (1)
Recurrence of well-differentiated astrocytomas and malignant transformation (1987) (1)
[Long-term results of the treatment of infantile medulloblastoma]. (1983) (1)
Brain metastasis from HER2-positive breast cancer: an evolving landscape. (2022) (1)
TEMOZOLOMIDE FOR RECURRENT INTRACRANIAL EPENDYMOMA OF THE ADULT: PATTERNS OF RESPONSE, SURVIVAL AND CORRELATIONS WITH MGMT PROMOTER METHYLATION (2014) (1)
P21.03 Efficacy of bevacizumab in a primary diffuse leptomeningeal glioneuronal tumor of the adult (2016) (1)
Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients. (2019) (1)
P01.116 Treatment with Dabrafenib in a patient with BRAF mutated recurrent ganglioglioma (2018) (1)
Ependymoma: current treatment options and a look to the future. (2013) (1)
Recurrent/progressive oligodendroglial tumors: A phase II study with temozolomide as first line chemotherapy. (2006) (1)
A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study. (2017) (1)
Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. (2018) (1)
ACTR-06. DOSE DENSE TEMOZOLOMIDE (TMZ) AS INITIAL TREATMENT FOR HIGH-RISK OLIGODENDROGLIAL TUMORS: LONG-TERM RESULTS OF A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY (2017) (1)
Does an Optimal Management of Brain Metastases from Oncogenic-Driver Non-Small Cell Lung Cancer Exist? (2019) (1)
P06.08SYSTEMIC TREATMENT OF MENINGIOMAS: IS THERE A ROLE FOR LONG-ACTING SOMATOSTATIN? (2014) (1)
Prevention Strategies for Brain Metastasis (2019) (1)
ACTR-20. EFFICACY OF INITIAL TEMOZOLOMIDE FOR HIGH-RISK LOW GRADE GLIOMAS IN A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY: A POST-HOC ANALYSIS WITHIN MOLECULAR SUBGROUPS OF WHO 2016 (2019) (1)
Primary Central Nervous System Lymphomas (1997) (1)
Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial (2015) (1)
TMIC-01. STAT3 EXPRESSION IN BRAIN METASTASES FROM BREAST CANCER: CORRELATIONS WITH DIFFERENT MOLECULAR SUBTYPES AND CLINICAL OUTCOME (2022) (1)
Molecular Genetic, Host-Derived and Clinical Determinants of Long-Term Survival in Glioblastoma: First Results from the Brain Tumor Funders' Collaborative Consortium (2016) (1)
Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9-15, 2014). (2014) (1)
Choosing appropriate chemotherapy for diffusely infiltrating WHO grade II gliomas in adults (2020) (1)
Prognostic factors in anaplastic astrocytomas after surgery and conventional radiotherapy (1991) (1)
Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery (2020) (1)
42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM (2020) (0)
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma (2015) (0)
Tumors of the Meninges (1993) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
P13.04 Practice patterns of diagnosis and management of leptomeningeal metastasis in Europe: results from a web-based survey (2016) (0)
Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature (2020) (0)
2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology) (2015) (0)
Third Annual Congress of the Italian Association of Neuro-Oncology (1993) (0)
Comprar Handbook Of Clinical Neurology, Vol. 105: Neuro-Oncology Part II | Wolfgang Grisold | 9780444535023 | Elsevier Internacional (2012) (0)
Highlights from the literature (1960) (0)
Abstract 653: Gliomas: methylation status of MGMT gene monitoring in plasma DNA of patients receiving chemotherapy with alkylating agents. (2013) (0)
Delayed radio necrosis following concentrated split course radio therapy a case (1982) (0)
Automatic Segmentation and Therapy Followup of Cerebral Glioma in DiffusionTensor Images (2010) (0)
Spinal epidural metastases (2016) (0)
SP-0572 CURRENT PRACTICE AND MOVING POINTS: PRIMARY BRAIN (2012) (0)
P-190 A prognostic factors analysis of fractionated stereotactic radiotherapy in the treatment of patients with brain metastases from non small cell lung carcinoma (2003) (0)
Evidence-based approaches to chemotherapy for gliomas (2021) (0)
Editorial: Neuro-oncology is moving ahead: new perspectives and critical issues. (2020) (0)
Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter? (2023) (0)
ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE (2018) (0)
R03Prognostic factors in glioblastoma patients treated with the nitrosourea fotemustine at first relapse after the Stupp regimen: results from the GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology) (2015) (0)
Khalida WaniTerri S. ArmstrongElizabeth Vera-BolanosAditya RaghunathanDavid Ellison • Richard GilbertsonBrian VaillantStewart GoldmanRoger J. PackerMaryam FouladiIan Pollack • Tom MikkelsenMichael PradosAntonio OmuroRiccardo SoffiettiAlicia LedouxCharmaine Wilson • Lihong LongMark R. GilbertKen Alda (2012) (0)
Supratotal Resection of Glioblastoma : Is Less More ?-1-# 1167 (2019) (0)
Resectable central nervous system (CNS) metastases from colorectal cancer (CRC): Patient characteristics, outcome, and molecular correlations between primary tumor and metastases. (2017) (0)
Author Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis (2018) (0)
P12.04GLIOMATOSIS CEREBRI: IS THERE A ROLE FOR SURGERY OTHER THAN BIOPSY? (2014) (0)
Tumors of the Central Nervous System: Therapeutic Approaches (2019) (0)
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression. (2013) (0)
OS06.7A METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy (2021) (0)
P13.19HYPOFRACTIONATED RADIOTHERAPY IN PATIENTS WITH HIGH GRADE GLIOMAS AND POOR PROGNOSTIC FACTORS: A RETROSPECTIVE STUDY (2014) (0)
P17.58DETECTION OF HUMAN PAPILLOMA VIRUS DNA IN A SUBSET OF GLIOBLASTOMA SAMPLES (2014) (0)
P08.58 Upfront chemotherapy in grade III gliomas: an institutional retrospective series. (2016) (0)
Contributors List (2021) (0)
Diffusion Tensor Imaging-based Histogram Analysis for detection and quantification of low-grade gliomas structural changes during chemotherapy (2013) (0)
P09.41 Single agent Bevacizumab in recurrent glioblastoma after a second line chemotherapy with Fotemustine. The Italian Association of Neuro Oncology experience (2017) (0)
P08.33 GLIOSTRY (Glioblastoma Registry) of the AINO (Italian Association of Neuro-Oncology): final analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first progression following chemoradiation. (2016) (0)
OS3.1 IDH-wild type grade II gliomas: a retrospective series of AINO (Italian Association of Neuro-Oncology) (2018) (0)
S100A9 mediates resistance of brain metastasis to radiation therapy. (2018) (0)
Highlights from the literature (2014) (0)
Biological Basis of Therapies (1993) (0)
OS5.5 Supratotal resection in low grade gliomas (LGGs): feasibility and clinical impact. (2016) (0)
Primary limphomas of the brain (1987) (0)
P14.85 Brain metastasis from Hodgkin’s Lymphoma: case report and literature review (2019) (0)
P04.09 Patterns of care and impact on survival of first salvage therapy in high-risk grade II gliomas following initial temozolomide (2019) (0)
P05.49 Extra-neural metastases from a sacro-coccygeal myxopapillary ependymoma: a case report (2018) (0)
[Cerebral metastatis. Diagnostic and therapeutic features]. (2000) (0)
Central Nervous System Metastases (2020) (0)
IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study. (2018) (0)
SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine (2021) (0)
OS03.7 Does improved intracranial control from whole brain radiation therapy translate to improved overall survival in patients with limited competing risk from systemic disease? A secondary analysis of EORTC 22952–26001. (2017) (0)
Natural history and management of well differentiated astrocytomas of the cerebral hemispheres (1988) (0)
RADI-03. A strategy to personalize the use of radiation in patients with brain metastasis based on S100A9-mediated resistance (2021) (0)
Adverse effects of antiepileptic drugs in brain tumors: Preliminary data of a multi-institutional survey. Are new antiepileptic drugs less toxic? (2005) (0)
P15.10COGNITIVE AND FUNCTIONAL STATUS OF PATIENTS AND QUALITY OF LIFE OF CAREGIVERS: A PROSPECTIVE STUDY IN A COHORT OF RECURRENT GLIOBLASTOMAS. (2014) (0)
PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY OF TREATMENT FOR LOW GRADE GLIOMAS IN ELOQUENT AREAS (2014) (0)
Utility and limits of an imaging follow-up in evaluation of response and evolution of cerebral tumors after radiotherapy. (1990) (0)
[Future prospects]. (2007) (0)
361PEffect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer (2017) (0)
Epilepsy in CNS Metastases (2019) (0)
Ependymomas of childhood: pathological study of 100 cases for survival analysis (1989) (0)
Bevacizumab and temozolomide in secondary gliomatosis from gemistocytic astrocytoma: a case report (2012) (0)
OS1.4 Liquid biopsy of the CSF in a series of GBM patients: preliminary results (2019) (0)
Monitoring of cognitive functions and quality of life, in glioblastomas treated with regorafenib (2021) (0)
CTNI-25. REGORAFENIB IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTICENTRIC REAL-LIFE STUDY (2022) (0)
A CAD system for cerebral glioma in Magnetic Resonance Diffusion Tensor Images: semiautomatic segmentation and therapy follow up (2012) (0)
Efficacy of topiramate in patients with gliomas (2007) (0)
Beyond Semantics: The Need to Better Categorize Patients With Cancer (2013) (0)
Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role? (2017) (0)
Fourth Congress of the Italian Association of Neuro-Oncology (1995) (0)
OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma patients (2018) (0)
Editorial: Hot Topics in Neuro-Oncology. (2018) (0)
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases (2023) (0)
Advocacy for brain tumours (2019) (0)
Is there a Role for Bevacizumab in Non-Glial Tumors? (2015) (0)
Table of Content Editorial 4 (2014) (0)
P05.47 Long-lasting response in spinal metastases from ALK rearranged Non-Small-Cell Lung Cancer treated with different ALK inhibitors (2018) (0)
Sixteenth Meeting of the European Neurological Society 27–31 May 2006, Lausanne, Switzerland (2006) (0)
Glomus Tumors, Paragangliomas (1997) (0)
Highlights from the literature (1957) (0)
MS-22NEOPLASTIC MENINGITIS FROM EPENDYMOMAS OF THE ADULT: A RETROSPECTIVE ANALYSIS. (2014) (0)
431PBEVACIZUMAB AND FOTEMUSTINE FOR RECURRENT HIGH GRADE GLIOMAS. (2014) (0)
Seventeenth Meeting of the European Neurological Society 16–20 June 2007, Rhodes, Greece (2007) (0)
Classification and Nosography of Neuroepithelial Tumors (1993) (0)
Radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) in the treatment of brain metastases (2006) (0)
NIMG-53. GLUTAMATE/GABA RATIO ON MRS IS ELEVATED IN PATIENTS WITH LOWER GRADE GLIOMAS AND SEIZURES (2020) (0)
High speed autoradiography on brain tissue sections. (1981) (0)
Brain Tumour-Related Epilepsy: Impact of Grading and Treatments in a Cohort of Molecularly Defined Lower-Grade Gliomas (2022) (0)
P09.08 Clinical validation of integrated diagnosis in low-grade glioma (LGG). (2016) (0)
GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen. (2015) (0)
P01.054 Patterns of first tumor progression and impact on survival of salvage therapies in low-grade gliomas following initial chemotherapy with temozolomide (2018) (0)
8703 ORAL Bevacizumab and Fotemustine for Recurrent Glioblastoma – Final Results of a Multicenter Phase II Study of AINO (Italian Association of Neuro-Oncology) (2011) (0)
Center for Neuro-Oncology in Turin (Italy) (2018) (0)
O10.06A PHASE II STUDY OF AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY) ON BEVACIZUMAB AND FOTEMUSTINE FOR RECURRENT GLIOBLASTOMA: OUTCOME, PATTERNS OF RELAPSE AND SALVAGE TREATMENTS (2014) (0)
PS1 - 177 Diagnosing and Treating Leptomeningeal Metastasis across Europe: A Web-Based Survey (2016) (0)
Fifth congress of the Italian association of Neuro-Oncology october 2-3-4, 1997 Pavia, Salice Terme (2005) (0)
PCSM-08EFFICACY AND TOLERABILITY OF LACOSAMIDE IN PATIENTS WITH GLIOMA AND SEIZURES: A PROSPECTIVE STUDY (2015) (0)
Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY). (2016) (0)
[Chemotherapy of cerebral tumours: data on malignant gliomas (author's transl)]. (1978) (0)
Highlights from the literature (2015) (0)
Frequency, patterns of care, and outcome of neoplastic meningitis (NM) from solid tumors in regione Piemonte, Italy: A prospective survey from a cancer network. (2010) (0)
[Radiotherapy of cerebral metastases]. (1984) (0)
Genomics and targeted therapy for meningiomas (2015) (0)
P05.30 Intracranial meningiomas: a systematic analysis of prognostic factors for recurrence in a large surgical series (2018) (0)
Gliomatosis cerebri with oligodendrocytic components: description of 1 case (2003) (0)
CMET-43. COMPARISON OF LOCAL CONTROL OF BRAIN METASTASES WITH STEREOTACTIC RADIOSURGERY VERSUS SURGICAL RESECTION: A SECONDARY ANALYSIS OF EORTC 22952–26001 (2017) (0)
Highlights from the Literature A phase II trial of neratinib for patients with HER2-positive breast cancer and brain MR studies of glioblastoma models treated with dual PI3K/mTOR inhibitor and (2016) (0)
MORPHOLOGICAL APPROACHES TO THE PROBLEM OF NEO‐VASCULARIZATION IN MALIGNANT GLIOMAS: 118 (1987) (0)
METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy. (2021) (0)
BMET-22. DOES WHOLE BRAIN RADIOTHERAPY FOR OLIGOMETASTATIC BRAIN METASTASES TRANSLATE INTO A SURVIVAL BENEFIT FOR PATIENTS WITH A LIMITED COMPETING RISK FROM EXTRA-CRANIAL DISEASE? A SECONDARY ANALYSIS OF EORTC 22952-26001 (2016) (0)
ACTR-67. PATTERNS OF CARE AND IMPACT ON SURVIVAL OF FIRST SALVAGE THERAPY IN HIGH-RISK GRADE II GLIOMAS FOLLOWING INITIAL TEMOZOLOMIDE (2019) (0)
R24Efficacy and safety of the VEGF inhibitor bevacizumab in combination with fotemustine for high-grade gliomas (2015) (0)
Choroid Plexus Tumors (1993) (0)
Abstract PO-068: S100A9 mediates radiation resistance of brain metastasis (2021) (0)
CMET-40. LONG-LASTING RESPONSE IN SPINAL METASTASES FROM ALK REARRANGED NON-SMALL-CELL LUNG CANCER TREATED WITH DIFFERENT ALK INHIBITORS (2018) (0)
Prognostic value of histological features in cerebral astrocytomas (1986) (0)
Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era (2022) (0)
Brain Metastases – Clinical Challenges and Recent Advances (2019) (0)
ACTR-72. IDH-WILD TYPE GRADE II GLIOMAS: A RETROSPECTIVE SERIES OF ITALIAN ASSOCIATION OF NEURO-ONCOLOGY (2018) (0)
Preoperative chemotherapy as a new strategy of treatment for low-grade gliomas in eloquent areas: A phase II study. (2014) (0)
Online Database Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2018) (0)
SURG-10. PROGNOSTIC IMPORTANCE OF THE EXTENT OF RESECTION IN IDH-WILD TYPE GRADE II ASTROCYTOMAS ACCORDING TO PTERT MUTATION (2020) (0)
Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery (2020) (0)
Sistemi di Computer-Assisted Detection e di Analisi di Dati Bio-medici (2013) (0)
EPID-27GLIOSTRY (GLIOBLASTOMA REGISTRY) OF THE AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY): ANALYSIS OF FACTORS INFLUENCING SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING THE NITROSOUREA FOTEMUSTINE AT FIRST PROGRESSION FOLLOWING THE STUPP REGIMEN (2015) (0)
THE ADDITION OF THIOTEPA AND RITUXIMAB TO HIGH DOSES OF ANTIMETABOLITES SIGNIFICANTLY IMPROVES OUTCOME IN PRIMARY CNS LYMPHOMA: THE FIRST RANDOMIZATION OF THE IELSG #32 TRIAL (2015) (0)
[Efficacy of liposomal cytarabine in neoplastic meningitis]. (2007) (0)
Assessement of clinical prognostic factors in elderly glioblastoma patients: An unmet need (2021) (0)
BSCI-02. METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy (2021) (0)
Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2016) (0)
P16.34BEVACIZUMAB TREATMENT FOR ACOUSTIC NEURINOMA IN NEUROFIBROMATOSIS TYPE 2: A CASE REPORT (2014) (0)
Highlights from the literature (1960) (0)
Neoplastic meningitis: Clinico-diagnostic aspects[Meningite neoplastica: Aspetti clinico-diagnostici] (2006) (0)
Whole-braın radıotherapy versus observatıon after radıosurgery or surgery of 1-3 braın metastases-results of the eortc 22952-26001 phase ııı study (2009) (0)
P05.89 Comparison of local control of brain metastases with stereotactic radiosurgery versus surgical resection: A secondary analysis of EORTC 22952–26001 (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Riccardo Soffietti?

Riccardo Soffietti is affiliated with the following schools:

Consorzio ICoN
University of Milan
Marmara University
University of Colorado
University of Toronto
University of Turin